HZNP Horizon Therapeutics Public Ltd Co

Price (delayed)

$109.96

Market cap

$24.84B

P/E Ratio

45.07

Dividend/share

N/A

EPS

$2.44

Enterprise value

$26.6B

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise ...

Highlights
HZNP's net income has surged by 85% since the previous quarter
HZNP's gross profit has soared by 74% year-on-year and by 18% since the previous quarter
Horizon Therapeutics's EPS has soared by 85% from the previous quarter but it has decreased by 14% YoY
The company's debt has surged by 119% YoY
The stock's price to earnings (P/E) is 10% more than its last 4 quarters average of 41.3

Key stats

What are the main financial stats of HZNP
Market
Shares outstanding
225.89M
Market cap
$24.84B
Enterprise value
$26.6B
Valuations
Price to earnings (P/E)
45.07
Price to book (P/B)
6.07
Price to sales (P/S)
9.68
EV/EBIT
61.07
EV/EBITDA
36.02
EV/Sales
10.4
Earnings
Revenue
$2.56B
EBIT
$435.58M
EBITDA
$738.37M
Free cash flow
$527.62M
Per share
EPS
$2.44
Free cash flow per share
$2.34
Book value per share
$18.12
Revenue per share
$11.36
TBVPS
$17.85
Balance sheet
Total assets
$8.21B
Total liabilities
$4.13B
Debt
$2.58B
Equity
$4.07B
Working capital
$1.32B
Liquidity
Debt to equity
0.63
Current ratio
2.55
Quick ratio
1.82
Net debt/EBITDA
2.38
Margins
EBITDA margin
28.9%
Gross margin
75.9%
Net margin
20.3%
Operating margin
17.6%
Efficiency
Return on assets
7.4%
Return on equity
13.2%
Return on invested capital
13%
Return on capital employed
5.9%
Return on sales
17%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HZNP stock price

How has the Horizon Therapeutics stock price performed over time
Intraday
-0.37%
1 week
1.8%
1 month
1.6%
1 year
40.52%
YTD
50.32%
QTD
17.43%

Financial performance

How have Horizon Therapeutics's revenue and profit performed over time
Revenue
$2.56B
Gross profit
$1.94B
Operating income
$450.43M
Net income
$518.16M
Gross margin
75.9%
Net margin
20.3%
The company's operating margin has surged by 112% YoY and by 9% QoQ
HZNP's net income has surged by 85% since the previous quarter
HZNP's gross profit has soared by 74% year-on-year and by 18% since the previous quarter
Horizon Therapeutics's revenue has soared by 68% YoY and by 17% from the previous quarter

Growth

What is Horizon Therapeutics's growth rate over time

Valuation

What is Horizon Therapeutics stock price valuation
P/E
45.07
P/B
6.07
P/S
9.68
EV/EBIT
61.07
EV/EBITDA
36.02
EV/Sales
10.4
Horizon Therapeutics's EPS has soared by 85% from the previous quarter but it has decreased by 14% YoY
The stock's price to earnings (P/E) is 10% more than its last 4 quarters average of 41.3
HZNP's price to book (P/B) is 96% higher than its 5-year quarterly average of 3.1 and 30% higher than its last 4 quarters average of 4.7
The equity has soared by 72% year-on-year and by 6% since the previous quarter
HZNP's price to sales (P/S) is 126% more than its 5-year quarterly average of 4.3 and 16% more than its last 4 quarters average of 8.4
Horizon Therapeutics's revenue has soared by 68% YoY and by 17% from the previous quarter

Efficiency

How efficient is Horizon Therapeutics business performance
HZNP's ROE has soared by 65% from the previous quarter but it is down by 47% YoY
Horizon Therapeutics's return on assets has surged by 61% QoQ but it has decreased by 39% YoY
Horizon Therapeutics's ROS has increased by 16% from the previous quarter
HZNP's return on invested capital is up by 4% since the previous quarter

Dividends

What is HZNP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HZNP.

Financial health

How did Horizon Therapeutics financials performed over time
The total assets is 99% more than the total liabilities
The company's total liabilities has surged by 90% YoY and by 3.6% QoQ
The total assets has soared by 81% YoY and by 4.6% from the previous quarter
The company's debt is 37% lower than its equity
The company's debt has surged by 119% YoY
The equity has soared by 72% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.